A genome-editing strategy for potential Alzheimer’s disease therapy

HKUST scientists develop genome-editing strategy for potential Alzheimer’s disease therapy
The level of amyloid (white shades in area encircled by green dotted lines) – the protein thought to drive neurodegeneration in AD, is high in the brain of AD mouse (left) and reduces after the administration of the genome editing therapy throughout the brain (right). Credit: HKUST

An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a novel strategy using brain-wide genome-editing technology that can reduce Alzheimer’s disease (AD) pathologies in genetically modified AD mouse models. This advanced technology offers immense potential to be translated as a novel long-acting therapeutic treatment for AD patients.

Read more…